Cognition Therapeutics Inc (CGTX) Stock Price, Quote & News

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as ge...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 481 2210

Website: www.cogrx.com

Address:

2500 Westchester Ave., Purchase, United States

nostic Dec. 24 at 8:21 PM

$CGTX haha… Happy Holidays Cognitians!

0 · Reply

GibsonFlyingV Dec. 24 at 6:32 PM

$CGTX a Green Day is always good big or small. Wishing all of you happy holidays everyone! Be safe!

0 · Reply

TwizzlersForSale Dec. 24 at 5:01 PM

$CGTX My average here is $2.07/share. Just curious if this investment plans to grow or if I’ll be stuck in financial doomsday forever at CGTX? Thoughts? I invested to help the company grow and continue development of their lead candidate CT1812, but I’ve only seen a negative return since putting my money behind Cognition. Thoughts welcome.

4 · Reply

Rjcamel2355 Dec. 24 at 2:46 PM

$CGTX another buying opportunity, I refuse to be shook out or give up my shares with such great things on the horizon for the company. Ill continue to increase my position on dips like these.

1 · Reply

Beach_Bums Dec. 24 at 10:31 AM

$CGTX 5k shares in and im staying the course. I believe in the vision of this company and the upside that it has to offer. I feel within the next few months we will get our 🚀 news and the patience will have been worth it.

1 · Reply

byeonkh Dec. 23 at 11:02 PM

$CGTX Volume spiked to 2.36M (~2.6× avg). Price fell from $1.61 to $1.37, then closed around $1.40. Feels like more than retail panic — possibly institutional selling met by dip buyers. Could also be dilution fears or simple overreaction.

1 · Reply

Aimforsuccess Dec. 23 at 9:02 PM

$CGTX Financial terrorism at its best in my opinion.

0 · Reply

mcclayjd40 Dec. 23 at 8:43 PM

$CGTX The company will sell shares to raise money, but not at these prices. They’ll put out some good news which will spike the price and then sell into the higher volume . It minimizes dilution and maximizes the return on the sale.

1 · Reply

IzErbdEIn Dec. 23 at 7:50 PM

$CGTX with any prediction, always account for a 10% variance in either direction...the market is never an exact science, but the math is horeshoes and hand grenades for sure

0 · Reply

IzErbdEIn Dec. 23 at 7:07 PM

$CGTX

0 · Reply

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 20, 2025, 4:01 PM EST - 4 weeks ago

Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

Nov 13, 2025, 7:36 AM EST - 5 weeks ago

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease

Nov 6, 2025, 7:30 AM EST - 6 weeks ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

Sep 3, 2025, 7:30 AM EDT - 4 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

Sep 2, 2025, 4:00 PM EDT - 4 months ago

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

Aug 27, 2025, 8:53 PM EDT - 4 months ago

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

Aug 26, 2025, 4:00 PM EDT - 4 months ago

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 26, 2025, 10:08 AM EDT - 4 months ago

Cognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" Rating

Aug 12, 2025, 4:00 PM EDT - 4 months ago

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

Jul 29, 2025, 7:30 AM EDT - 5 months ago

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

Jul 21, 2025, 7:30 AM EDT - 5 months ago

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

Jul 16, 2025, 7:30 AM EDT - 5 months ago

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

Jul 10, 2025, 7:30 AM EDT - 5 months ago

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

Jul 1, 2025, 7:30 AM EDT - 6 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

Jun 25, 2025, 7:30 AM EDT - 6 months ago

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

Jun 3, 2025, 7:30 AM EDT - 7 months ago

Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

May 28, 2025, 7:30 AM EDT - 7 months ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

May 9, 2025, 7:30 AM EDT - 8 months ago

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

May 7, 2025, 7:30 AM EDT - 8 months ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

Apr 1, 2025, 7:30 AM EDT - 9 months ago

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Mar 25, 2025, 7:30 AM EDT - 9 months ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

Mar 20, 2025, 1:15 PM EDT - 9 months ago

Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:00 AM EDT - 9 months ago

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:05 PM EDT - 10 months ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

Mar 12, 2025, 4:05 PM EDT - 10 months ago

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

Mar 10, 2025, 7:30 AM EDT - 10 months ago

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

Feb 27, 2025, 7:30 AM EST - 10 months ago

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Feb 25, 2025, 7:30 AM EST - 10 months ago

Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

Jan 30, 2025, 7:30 AM EST - 11 months ago

Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Jan 8, 2025, 4:14 PM EST - 1 year ago

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Dec 18, 2024, 11:06 AM EST - 1 year ago

Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?

Dec 18, 2024, 7:22 AM EST - 1 year ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Nov 26, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Nov 25, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Nov 12, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Oct 31, 2024, 4:15 PM EDT - 1 year ago

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Oct 29, 2024, 12:55 PM EDT - 1 year ago

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

Aug 22, 2024, 7:31 AM EDT - 1 year ago

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

Aug 11, 2024, 12:55 AM EDT - 1 year ago

Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

Jul 29, 2024, 7:14 AM EDT - 1 year ago

Cognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer's disease

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients

nostic Dec. 24 at 8:21 PM

$CGTX haha… Happy Holidays Cognitians!

0 · Reply

GibsonFlyingV Dec. 24 at 6:32 PM

$CGTX a Green Day is always good big or small. Wishing all of you happy holidays everyone! Be safe!

0 · Reply

TwizzlersForSale Dec. 24 at 5:01 PM

4 · Reply

Rjcamel2355 Dec. 24 at 2:46 PM

$CGTX another buying opportunity, I refuse to be shook out or give up my shares with such great things on the horizon for the company. Ill continue to increase my position on dips like these.

1 · Reply

Beach_Bums Dec. 24 at 10:31 AM

1 · Reply

byeonkh Dec. 23 at 11:02 PM

1 · Reply

Aimforsuccess Dec. 23 at 9:02 PM

$CGTX Financial terrorism at its best in my opinion.

0 · Reply

mcclayjd40 Dec. 23 at 8:43 PM

1 · Reply

IzErbdEIn Dec. 23 at 7:50 PM

$CGTX with any prediction, always account for a 10% variance in either direction...the market is never an exact science, but the math is horeshoes and hand grenades for sure

0 · Reply

IzErbdEIn Dec. 23 at 7:07 PM

$CGTX

0 · Reply